Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Clinical and Vaccine Immunology : CVI
I TamayoCarlos Gamazo

Abstract

The mechanisms that underlie the potent Th1-adjuvant capacity of poly(methyl vinyl ether-co-maleic anhydride) nanoparticles (NPs) were investigated. Traditionally, polymer NPs have been considered delivery systems that promote a closer interaction between antigen and antigen-presenting cells (APCs). Our results revealed that poly(anhydride) NPs also act as agonists of various Toll-like receptors (TLRs) (TLR2, -4, and -5), triggering a Th1-profile cytokine release (gamma interferon [IFN-gamma], 478 pg/ml versus 39.6 pg/ml from negative control; interleukin-12 [IL-12], 40 pg/ml versus 7.2 pg/ml from negative control) and, after incubation with dendritic cells, inducing a 2.5- to 3.5-fold increase of CD54 and CD86 costimulatory molecule expression. Furthermore, in vivo studies suggest that NPs actively elicit a CD8(+) T-cell response. Immunization with empty NPs resulted in a significant delay in the mean survival date (from day 7 until day 23 postchallenge) and a protection level of 30% after challenge against a lethal dose of Salmonella enterica serovar Enteritidis. Taken together, our results provide a better understanding of how NPs act as active Th1 adjuvants in immunoprophylaxis and immunotherapy through TLR exploitation.

References

Jun 29, 2002·The Journal of Biological Chemistry·Trude H FloTerje Espevik
Oct 22, 2002·Journal of Controlled Release : Official Journal of the Controlled Release Society·P ArbósJ M Irache
Jan 16, 2003·Immunology Letters·Shizuo Akira, Hiroaki Hemmi
Feb 4, 2003·Nature Reviews. Immunology·Giorgio Trinchieri
May 24, 2003·Vaccine·Giuseppe Del Giudice
Jun 10, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Steven B MizelA Phillip West
Aug 23, 2003·Immunity·Bruce Beutler
Jan 22, 2004·Current Opinion in Immunology·Caetano Reis e Sousa
Jul 6, 2004·Immunological Reviews·Bali Pulendran
Oct 14, 2004·Immunology and Cell Biology·Nikolai Petrovsky, Julio César Aguilar
Oct 14, 2004·Immunology and Cell Biology·Erik B Lindblad
Mar 26, 2005·Immunological Reviews·Ian R RifkinAnn Marshak-Rothstein
Apr 7, 2005·Nature Medicine·Achal PashineJeffrey B Ulmer
Jun 23, 2005·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hesham H SalmanJuan M Irache
Sep 28, 2005·International Immunology·Stephen John JenkinsAdrian Paul Mountford
Nov 30, 2005·Critical Reviews in Therapeutic Drug Carrier Systems·Sergio A Galindo-RodriguezEric Doelker
Feb 16, 2006·International Journal of Cancer. Journal International Du Cancer·Amla ChopraEdward P Cohen
Oct 20, 2006·Journal of Nanoscience and Nanotechnology·Hesham H SalmanJuan M Irache
Oct 20, 2006·Journal of Nanoscience and Nanotechnology·Sara GómezJuan M Irachel
Jan 5, 2007·The Journal of Immunology : Official Journal of the American Association of Immunologists·Juan J LasarteClaude Leclerc
Jan 26, 2007·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·B S RomanJ M Irache
Feb 24, 2007·Nature Reviews. Immunology·Giorgio Trinchieri, Alan Sher
May 5, 2007·Nature Medicine·Holger KanzlerRobert L Coffman
Jun 15, 2007·Nature Reviews. Microbiology·Bruno Guy
Nov 17, 2007·Carbohydrate Research·Rongsong Xu, Zi-Hua Jiang
Jun 17, 2008·International Journal of Pharmaceutics·Yvonne PerrieVincent W Bramwell
Sep 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carla A Da SilvaJack A Elias
Sep 25, 2008·International Journal of Pharmaceutics·Christian WischkeDirk R Lorenzen
Dec 20, 2008·Expert Review of Vaccines·Jamie F S MannValerie A Ferro
Dec 26, 2008·Clinical and Vaccine Immunology : CVI·Christoph Georg BaumsPeter Valentin-Weigand
Jan 14, 2009·Proceedings of the National Academy of Sciences of the United States of America·Fiona A SharpEd C Lavelle

❮ Previous
Next ❯

Citations

Sep 15, 2015·Expert Opinion on Drug Delivery·Małgorzata Anna MarćCarlos Gamazo
Feb 9, 2016·Zoonoses and Public Health·A D Wales, R H Davies
Jul 12, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Juliana De Souza RebouçasCarlos Gamazo
May 9, 2012·International Journal of Pharmaceutics·J F Correia-PintoM J Alonso
Mar 29, 2011·Acta Biomaterialia·Maria P TorresBalaji Narasimhan
Apr 5, 2011·Trends in Biotechnology·Stacey L DementoTarek M Fahmy
Jul 28, 2016·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Gregory Lee Szeto, Erin B Lavik
Jan 24, 2015·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Carlos GamazoJ M Irache
Jul 20, 2011·Journal of Polymer Science. Part B, Polymer Physics·Bret D UleryCato T Laurencin
Apr 25, 2013·Journal of Biomedical Materials Research. Part a·Ryan J Love, Kim S Jones
Jul 30, 2014·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Mee Rie SheenSteven Fiering
Apr 3, 2016·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Aniruddha Roy, Shyh-Dar Li
Apr 13, 2012·Journal of Biomedicine & Biotechnology·Juliana De Souza RebouçasCarlos Gamazo
Nov 21, 2012·FEMS Immunology and Medical Microbiology·Neeta Jain-GuptaNammalwar Sriranganathan
Aug 28, 2013·Human Vaccines & Immunotherapeutics·Vijaya B JoshiAliasger K Salem
Jun 18, 2011·Veterinary Parasitology·Juan M IracheSocorro Espuelas
Oct 8, 2014·Immunotherapy·Carlos GamazoJuan M Irache
Jan 21, 2016·Annual Review of Biomedical Engineering·Balaji NarasimhanJulia E Vela Ramirez
Oct 13, 2016·Expert Opinion on Drug Delivery·Ana Brotons-CantoJuan M Irache
Feb 2, 2017·Therapeutic Delivery·Nirmal MarasiniIstvan Toth
Sep 12, 2018·Expert Opinion on Drug Delivery·Aoife M RodgersRyan F Donnelly
Jun 6, 2014·Clinical and Vaccine Immunology : CVI·Juliana De S RebouçasCarlos Gamazo
Nov 20, 2018·Nanotoxicology·Cheng Teng NgGyeong Hun Baeg
Dec 14, 2011·Expert Review of Vaccines·Raquel Da Costa MartinsCarlos Gamazo
Feb 1, 2020·Current Drug Targets·Razieh Mohammad JafariAhmad Reza Dehpour
Oct 27, 2018·The Journal of Pharmacology and Experimental Therapeutics·Emad I WafaAliasger K Salem
Nov 7, 2019·Veterinary Research·Santosh Dhakal, Gourapura J Renukaradhya
Dec 29, 2020·Frontiers in Bioengineering and Biotechnology·Teresia W MainaJodi L McGill
Apr 26, 2017·Advanced Drug Delivery Reviews·Julia E Vela RamirezNicholas A Peppas
Jul 20, 2021·Advanced Drug Delivery Reviews·Chao PanHeng-Liang Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.